| Literature DB >> 29774278 |
Akinola Stephen Oluwole1, Sunday Isiyaku2, Attahiru Aliyu Aliero3, Christian Nwosu2, Adamani William2, Elizabeth Elhassan4, Uwem Friday Ekpo1.
Abstract
There is a hypothesis that Mass drug administration (MDA) of ivermectin and albendazole for the treatment of onchocerciasis and lymphatic filariasis could have an impact on the burden of soil-transmitted helminthiasis (STH) in MDA communities. We, therefore, assessed the burden of STH (Ascaris lumbricoides, Trichuris trichiura, and hookworm) infections in nine communities from 3 LGAs (two MDA local government areas (LGAs) and one control LGA) in Kebbi State, Nigeria after 5-years (2010-2015) of MDA for onchocerciasis and/or lymphatic filariasis. We also administered questionnaire to obtain demographic information and history of MDA in the past five years. The three LGAs are Bagudo (Ivermectin MDA); Zuru (Ivermectin/Albendazole MDA) and Dandi (No MDA). The study was a cross sectional survey. The total number of people that complied with provision of stool samples and questionnaire were 1357 persons; stool samples collected were examined for STH infections in the three LGAs. Zuru LGA had the highest prevalence of STH (41.89, 95% CI: 37.08-46.81) followed by Dandi LGA (24.66, 95% CI: 20.69-28.97) and Bagudo LGA (3.36, 95% CI: 1.97-5.32). Prevalence of STH infection was not significantly different among age group and sex. Geometric mean intensity per gram of infection for both A. lumbricoides and Hookworm were highest in Zuru LGA with (1.16 GMI, 95% CI: 0.97-1.36) and (1.49 GMI, 95% CI: 1.29-1.70) respectively. Treatment coverage was less than 65% from 2010 to 2013 in the intervention LGAs. The study shows that STH is still a public health problem in Zuru LGA (IVM + ALB) and requires MDA of albendazole for STH control to continue, while Dandi LGA (No MDA history) requires MDA with albendazole to scale up treatment for STH control.Entities:
Keywords: Assessment; Control; Lymphatic filariasis; Mass drug administration; Onchocerciasis; Soil-transmitted helminthiasis
Year: 2017 PMID: 29774278 PMCID: PMC5952656 DOI: 10.1016/j.parepi.2017.01.002
Source DB: PubMed Journal: Parasite Epidemiol Control ISSN: 2405-6731
Fig. 1Map of Kebbi state showing implementation of MDA by LGAs with Nigeria (inset).
Selection of LGAs and study communities in Kebbi State.
| Criteria for selection | LGA selected | Communities | Year MDA treatment started in the LGA |
|---|---|---|---|
| Communities treated with Ivermectin only | Bagudo LGA | Giris Hausawa | MDA with Ivermectin started in 1997 for onchocerciasis |
| Kali | |||
| Kabaka | |||
| Communities treated with Ivermectin and Albendazole | Zuru LGA | Isgogo | MDA for onchocerciasis started in 1997 and Albendazole was added in 2010 for LF |
| Selchi | |||
| Tadurga | |||
| Communities without any history of MDA | Dandi LGA | Geza | No history MDA |
| Fingillah | |||
| Kyangakwai |
Fig. 2Flow chart on study adherence.
Treatment History in the three LGAs selected in Kebbi State.
| Variables | Bagudo (IVM only) n = 506 | Zuru (IVM + ALB) n = 413 | Dandi (No MDA) n = 438 |
|---|---|---|---|
| Treated with MDA before | |||
| Yes | 471 (93.08%) | 380 (92.01%) | 57 (13.01%) |
| No | 35 (6.92%) | 33(7.99%) | 381 (86.99%) |
| History of MDA in the last five years | |||
| MDA in 2010 | 115 (22.73) | 49 (11.86) | Not applicable |
| MDA in 2011 | 181 (35.77) | 83 (20.09) | Not applicable |
| MDA in 2012 | 244 (48.22) | 153 (37.05) | Not applicable |
| MDA in 2013 | 313 (61.86) | 335 (81.11) | Not applicable |
| MDA in 2014 | 469 (92.69) | 399 (96.61) | Not applicable |
Prevalence of STH by parasite species, sex and age group in the three LGAs selected in Kebbi State, Nigeria.
| Variable | Bagudo (IVM only) | Dandi (No MDA) | Zuru (IVM + ALB) | Total |
|---|---|---|---|---|
| STH | 3.36 (1.97–5.32)506 | 24.66 (20.69–28.97)438 | 41.89 (37.08–46.81)413 | 21.96 (19.78–24.26)1357 |
| 1.19 (0.44–2.56)506 | 15.07 (11.85–18.77)438 | 15.25 (11.92–19.09)413 | 9.95 (8.41–11.67)1357 | |
| Hookworm | 2.17 (1.09–3.86)506 | 12.33 (9.40–15.78)438 | 29.06 (24.72–33.69)413 | 13.63 (11.85–15.57)1357 |
| 0.20 (0.01–1.10)506 | 0.46 (0.06–1.64)438 | 0.24 (0.01–1.34)413 | 0.29 (0.08–0.75)1357 | |
| Prevalence by age group | ||||
| STH | ||||
| School age (5–15 years) | 3.72 (1.71–6.94)242 | 24.29 (18.65–30.66)210 | 41.60 (35.42–47.98)250 | 23.36 (20.28–26.67) 702 |
| Adult (> 15 years) | 3.03 (1.32–5.88)264 | 25.00 (19.52–31.14)228 | 42.33 (34.64–50.30)163 | 20.45 (17.43–23.75) 655 |
| p-Value | 0.806 | 0.912 | 0.883 | 0.213 |
| | ||||
| School age (5–15 years) | 0.83 (0.10–2.95)242 | 17.14 (12.30–22.93)210 | 12.00 (8.24–16.69)250 | 9.69 (7.60–12.12)702 |
| Adult (> 15 years) | 1.52 (0.41–3.83)264 | 13.16(9.06–18.25)228 | 20.25 (14.36–27.24)163 | 10.23 (8.032–12.81)655 |
| p-Value | 0.687 | 0.285 | 0.023 | 0.786 |
| Hookworm | ||||
| School age (5–15 years) | 2.48 (0.92–5.32)242 | 10.95 (7.07–15.98)210 | 32.0 (26.26–38.17)250 | 15.53 (12.93–18.42)702 |
| Adult (> 15 years) | 1.89 (0.62–4.36)264 | 13.60 (9.43–18.74) 228 | 24.54 (18.15–31.88)163 | 11.60 (9.25–14.31)655 |
| p-Value | 0.764 | 0.468 | 0.103 | 0.039 |
| Prevalence by sex | ||||
| STH | ||||
| Male | 3.32 (1.53–6.21)271 | 26.32 (20.72–32.54)228 | 45.03 (37.84–52.37)191 | 22.46 (19.40–25.76)690 |
| Female | 3.40 (1.48–6.60)235 | 22.86 (17.36–29.14)210 | 39.19 (32.73–45.95)222 | 21.44 (18.38–24.75)667 |
| p-Value | 1.00 | 0.438 | 0.231 | 0.694 |
| | ||||
| Male | 1.11 (0.23–3.20)271 | 15.79 (11.31–21.18)228 | 14.66 (9.97–20.49)191 | 9.71 (7.61–12.17)690 |
| Female | 1.28 (0.26–3.69)235 | 14.29(9.85–19.76)210 | 15.77(11.23–21.24)222 | 10.19 (8.00–12.75)667 |
| p-Value | 1.00 | 0.690 | 0.755 | 0.786 |
| Hookworm | ||||
| Male | 2.21 (0.82–4.77)271 | 12.28 (8.32–17.26)228 | 33.51 (26.86–40.68)191 | 14.20 (11.68–17.03)690 |
| Female | 2.13 (0.69–4.90)235 | 12.38 8.25–17.61)210 | 25.23 (19.65–31.47)222 | 13.04 (10.58–15.84)667 |
| p-Value | 1.00 | 1.00 | 0.065 | 0.580 |
n = number examined.
Geometric mean intensity (GMI) of STH by parasite species, sex and age group in the three LGAs selected in Kebbi State, Nigeria.
| Variable | Bagudo (IVM only) | Dandi (No MDA) | Zuru (IVM + ALB) | Total |
|---|---|---|---|---|
| 0.18 (− 0.18–0.55) | 1.06 (0.90–1.22) | 1.16 (0.97–1.36) | 1.07 (0.95–1.20) | |
| Hookworm | 0.13 (− 0.04–0.29) | 0.68 (0.50–0.85) | 1.49 (1.29–1.70) | 1.17 (1.02–1.33) |
| – | – | – | – | |
| Intensity by age group | ||||
| | ||||
| School age (5–15 years) | 0.55 (− 0.86 1.96) | 0.97 (0.77–1.16) | 1.25 (0.94–1.56) | 1.08 (0.91–1.25) |
| Adult (> 15 years) | 0 | 1.17 (0.90–1.44) | 1.09 (0.83–1.35) | 1.06 (0.88–1.25) |
| p-Value | 0.1573 | 0.3949 | 0.5843 | 0.7893 |
| Hookworm | ||||
| School age (5–15 years) | 0.12 (− 0.14–0.37) | 0.59 (0.28–0.90) | 1.62 (1.38–1.87) | 1.32 (1.11–1.53) |
| Adult (> 15 years) | 0.14 (− 0.17–0.45) | 0.74 (0.52–0.96) | 1.23 (0.88–1.59) | 0.96 (0.74–1.18) |
| p-Value | 0.8918 | 0.1126 | 0.0165 | 0.0194 |
| Intensity by sex | ||||
| | ||||
| Male | 0.37 (− 0.58–1.31) | 1.10 (0.88–1.33) | 1.34 (1.01–1.68) | 1.17 (0.98–1.36) |
| Female | 0 | 1.01 (0.79–1.24) | 1.03 (0.79–1.26) | 0.98 (0.82–1.14) |
| p-Value | 0.3173 | 0.8407 | 0.1147 | 0.1860 |
| Hookworm | ||||
| Male | 0.23 (0.09–0.56) | 0.75 (0.48–1.03) | 1.30 (1.07–1.53) | 1.08 (0.90–1.26) |
| Female | 0 | 0.59 (0.36–0.82) | 1.72 (1.37–2.06) | 1.28 (1.02–1.54) |
| p-Value | 0.1736 | 0.4760 | 0.1370 | 0.5672 |
GMI (g) = geometrical mean intensity per gram.